Hence, targeting LPS/TNF-α-induced osteoclastogenesis could be a promising therapeutic strategy to inhibit inflammatory bone loss in osteolytic diseases such as periodontitis, rheumatoid arthritis, and osteoporosis. The gene discussed is TNF; the disease is periodontitis.